One-Pen Insulin-Plus-GLP-1 Combos Work as Well as Taking Them Separately — With a Weight Advantage

Fixed-ratio combinations (IDegLira, iGlarLixi) and free combinations of basal insulin + GLP-1RA showed comparable HbA1c reduction (MD 0.07%, 95% CI -0.17 to 0.30), but free combinations produced significantly greater weight loss (-2.06 kg) and blood pressure reductions.

Network meta-analysis following PROSPERO registration (CRD42023409585). Eight databases searched through April 2023. 42 Phase III clinical trials (23,619 patients) with uncontrolled T2DM included. Treatments categorized as FRC, free combination, or neither. Primary outcomes: HbA1c, body weight, hypoglycemia. Secondary: blood pressure.

Many diabetes patients eventually need both insulin and a GLP-1 drug. This comprehensive analysis helps clinicians and patients choose between the convenience of a single-pen combination versus the potentially better metabolic outcomes of separate injections.

Treatment simplification is a major goal in diabetes management — fewer injections typically means better adherence. This analysis shows that fixed-ratio pens achieve comparable blood sugar control with the convenience of a single injection, though at a modest cost in weight loss and blood pressure benefits. For many patients, the adherence benefits of simpler regimens may outweigh the metabolic trade-offs.

Network meta-analysis comparing across trials rather than within direct head-to-head studies. The weight and blood pressure differences, while statistically significant, are modest in clinical terms. Different trial designs, patient populations, and dose titration protocols may introduce heterogeneity. Cost and availability differences between FRC and free combinations not assessed.